Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2580(2)] to PIAS1
- Suitable for: ICC/IF, WB, IHC-P
- Reacts with: Mouse, Rat, Human
Product nameAnti-PIAS1 antibody [EPR2580(2)]
See all PIAS1 primary antibodies
DescriptionRabbit monoclonal [EPR2580(2)] to PIAS1
Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
Unsuitable for: IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human PIAS1 aa 50-150. The exact sequence is proprietary.
- Human colon tissue. HepG2, Jurkat, 293T, Daudi cell lysates. ICC/IF: HeLa cells
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Dissociation constant (KD)KD = 2.10 x 10 -11 M Learn more about KD
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab109388 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 72 kDa.|
|IHC-P||1/100 - 1/250. Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol. Heat up to 98 degrees C, below boiling, and then let cool for 10-20 min.|
FunctionFunctions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling.
Tissue specificityExpressed in numerous tissues with highest level in testis.
PathwayProtein modification; protein sumoylation.
Sequence similaritiesBelongs to the PIAS family.
Contains 1 PINIT domain.
Contains 1 SAP domain.
Contains 1 SP-RING-type zinc finger.
DomainThe LXXLL motif is a transcriptional coregulator signature.
The SP-RING-type domain is required for promoting EKLF sumoylation.
Dimethylated by PRMT1 at Arg-303 in the late phase of interferon gamma (IFN-gamma) signaling, leading to preferential interaction with STAT1 and thus resulting in release of STAT1 from its target gene.
Cellular localizationNucleus speckle. Interaction with CSRP2 may induce a partial redistribution along the cytoskeleton.
- Information by UniProt
- AR interacting protein antibody
- DDXBP1 antibody
- DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1 antibody
Lane 1 : Anti-PIAS1 antibody [EPR2580(2)] (ab109388) at 1/500 dilution
Lane 2 : Anti-GST antibody [EPR4236] (ab111947) at 1/2000 dilution
All lanes : Recombinant Human PIAS1 protein (ab152888)
Lysates/proteins at 0.01 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 72 kDa
Observed band size: 98 kDa why is the actual band size different from the predicted?
Lane 1: 10 seconds.
Lane 2: 1 minute.
Blocking and dilution buffer: 5% NFDM /TBST.
Immunocytochemistry/ Immunofluorescence analysis of HeLa (human cervix adenocarcinoma epithelial cell) cells labeling PIAS1 with purified ab109388 at 1/500 dilution (4.6 µg/mL). Cells were fixed in 100% Methanol. Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/mL) dilution. DAPI (blue) was used as nuclear counterstain.
All lanes : Anti-PIAS1 antibody [EPR2580(2)] (ab109388) at 1/1000 dilution
Lane 1 : HepG2 cell lysates
Lane 2 : Jurkat cell lysates
Lane 3 : HEK-293 cell lysates
Lane 4 : Daudi cell lysates
Lysates/proteins at 10 µg per lane.
Predicted band size: 72 kDa
Immunohistochemical analysis of paraffin-embedded Human colon tissue using 1/100 ab109388.
Perform heat mediated antigen retrieval via the pressure cooker method before commencing with IHC staining protocol.
Equilibrium disassociation constant (KD)
Learn more about KD
Click here to learn more about KD
ab109388 has been referenced in 8 publications.
- Chanda A et al. Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer. PLoS One 12:e0177639 (2017). WB, IF ; Human . PubMed: 28493978
- Scortegagna M et al. The E3 ubiquitin ligase Siah1 regulates adrenal gland organization and aldosterone secretion. JCI Insight 2:N/A (2017). IHC . PubMed: 29212953
- Bogachek MV et al. Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem Cell Reports 7:1140-1151 (2016). PubMed: 27916539
- Du L et al. Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. Nat Commun 7:12326 (2016). IHC-P ; Human . PubMed: 27465491
- Campia I et al. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. PLoS One 10:e0126159 (2015). WB . PubMed: 25955018
- Toropainen S et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res 43:848-61 (2015). PubMed: 25552417
- Chiou HY et al. Hes-1 SUMOylation by protein inhibitor of activated STAT1 enhances the suppressing effect of Hes-1 on GADD45a expression to increase cell survival. J Biomed Sci 21:53 (2014). WB . PubMed: 24894488
- Li R et al. Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res 73:5742-53 (2013). WB ; Human . PubMed: 23884910